Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,523.94
(
0.68%
)
US TECH 100
29,124.80
(
1.47%
)
Dow Jones
50,731.42
(
0.30%
)
Brent Oil
96.31
(
-4.81%
)
Bitcoin
77,340.00
(
0.09%
)
News Focus
News Focus
Post# of 257628
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123010
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 141316

Monday, 10/29/2012 8:02:43 AM

Monday, October 29, 2012 8:02:43 AM

Post# of 257628
Ipsen’s 3Q12 sales of Dysport* were $75M, +31% YoY, but flat vs 1Q12 (#msg-75220031):

http://finance.yahoo.com/news/ipsen-third-quarter-first-nine-072000991.html

Botox sales in 2Q12 were $461M (#msg-78091233), so Botox is outselling Dysport worldwide by about 6:1. (AGN will report 3Q12 Botox sales tomorrow, 10/30/12).

*Including sales to Medicis (soon to be part of VRX).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today